-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Assessment methodologies in sleep medicine clinical trials
Elena A Wood,W Vaughn McCall
Clinical Trail Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis, Hong Vu & Andrew E Mulberg
Editorial: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Tribulations of trials for antibacterial drugs: interview with Joseph Kuti
Joseph Kuti
Interview: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation
-
Ulipristal acetate (ellaOne) for emergency contraception: review of the clinical evidence
Kristina Gemzell-Danielsson,Sharon T Cameron
Review Article: Clinical Investigation